Double-Punch immunotherapy trial aims to tame resistant blood cancer
NCT ID NCT06464185
Summary
This study is testing a combination of two advanced immunotherapies for people with B-cell Non-Hodgkin lymphoma that has come back or not responded to standard treatments. The goal is to see if using a bispecific antibody drug together with engineered immune cells (CAR-T cells) is safe and more effective. Researchers want to learn if this one-two punch can better control the cancer and help the treatment last longer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL NON HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Institute of Hematology and Blood Diseases Hospital ,Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, China
Conditions
Explore the condition pages connected to this study.